Market Snapshot

S&P Futures
4,162.00
Dow Futures
34,031.00
NASDAQ Futures
13,899.50

5.52$-0.12 -2.13%
At close    04:00 PM   
From: To:

Stock Snapshot

5.64
Prev. Close
5.61
Open
1.10B
Market Cap
12.43M
Number of Shares
5.24
Day Low
5.67
Day High
5.52
-
P/E Ratio
181.89M
Free Float in %
-0.36
EPS 2021
0.13
Book Value per Share
0.12
Cash Flow per Share
Ocugen, Inc. (OCGN)
Ocugen, Inc. (OCGN) stock rallied over -2.13% intraday to trade at $5.52 per share on NASDAQ. The stock opened with a fall of -0.53% at $5.61 and touched an intraday high of $5.67, rising 0.53% against the last close of $5.64. The stock went to a low of $5.24 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-04-21$6.65$6.50$6.50$6.76$5.83132,554,600
2021-04-20$5.61$5.52$5.52$5.67$5.2413,460,700
2021-04-19$5.39$5.64$5.64$5.93$5.2912,351,100
2021-04-16$5.92$5.78$5.78$5.99$5.5117,410,100
2021-04-15$6.86$6.15$6.15$6.89$6.0618,546,800
2021-04-14$6.75$6.90$6.90$7.49$6.6832,764,300
2021-04-13$6.84$6.71$6.71$6.98$6.5513,071,300
2021-04-12$6.94$6.68$6.68$7.08$6.6611,063,500
2021-04-09$6.79$6.96$6.96$7.25$6.7618,216,000
2021-04-08$7.07$6.91$6.91$7.33$6.6521,545,300
2021-04-07$6.40$6.89$6.89$8.25$6.2886,840,500
Ocugen, Inc.
5 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States

http://www.ocugen.com
484 328 4701
Employees
15
Sector
Healthcare
Sales or Revenue
40,000
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30
Dr. Shankar Musunuri M.B.A., Ph.D., MBA
Co-Founder, Chairman & CEO
Dr. Uday B. Kompella Ph.D.
Founder & Independent Director
Mr. Sanjay S. Subramanian M.B.A.
Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec.
Ocugen, Inc.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.